Simulated breast milk phospholipid added with enriched sphingomyelin as well as preparation method and application of simulated breast milk phospholipid

Abstract

The invention discloses simulated breast milk phospholipid added with enriched sphingomyelin and a preparation method and application thereof, and belongs to the technical field of phospholipid processing. In order to solve the technical problems that in the prior art, infant inflammation and anaphylaxis are caused by breast milk phospholipids, and fat utilization is insufficient, the simulated breast milk phospholipids added with enriched sphingomyelin are provided, a more accurate compounding proportion is obtained through a Python scoring method, and the simulated breast milk phospholipids more similar to healthy breast milk are obtained; the relative content of sphingomyelin in a yak ghee phospholipid enrichment product is improved through enrichment reaction, and the quality and nutritional value of simulated breast milk phospholipid are improved. The simulated breast milk phospholipid provided by the invention has relatively high milk fat globule membrane and phospholipid formation rate, and relatively high quality and safety; the composition can be used for preparing infant formula milk powder, reducing infant inflammation and anaphylaxis and improving the fat utilization rate.

Description

Technical Field

[0001] The invention belongs to the technical field of phospholipid processing, and particularly relates to simulated breast milk phospholipids added with enriched sphingomyelin, and a preparation method and application thereof. Background Art

[0002] Breast milk is the most ideal nutritional requirement for newborns. It has a reasonable and balanced composition and is rich in macronutrients such as protein, fat and lactose. Among them, lipids are an important source of energy. Breast milk contains 3%-5% lipids, and phospholipids account for about 1% of the total lipids in breast milk. Phospholipids are a class of polar substances containing phosphorus. According to the molecular structure of phospholipids, they can be divided into two categories, namely glycerophospholipids (GPLs) and sphingolipids; the four main substances in glycerophospholipids are phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI) and phosphatidylserine (PS); the main sphingolipid in breast milk is sphingomyelin (SM), which has a fatty acid acyl chain, which is combined with an n atom from serine. About 65% of phospholipids are distributed in the milk fat globule membrane. Combined with the research results of recent years on the nutritional function of breast milk lipids and the digestion, absorption and metabolism of infants and young children, it can be seen that breast milk phospholipids are more beneficial to the development of infants' brains than traditional plant phospholipids (soybean lecithin, sunflower lecithin) and animal phospholipids (egg yolk lecithin, milk lecithin), while reducing the occurrence of inflammation and allergic reactions in infants and young children.

[0003] At present, due to the influence of external environment and psychological factors, the market demand for infant formula is constantly expanding when breast milk is not available or allowed. However, infants fed with formula milk may experience "insufficient fat utilization", that is, digestion affects metabolism. Although many infant formulas (IF) use milk fat globule membrane (MFGM) and exogenous phospholipids to simulate the interface of breast milk fat globules, due to damage during production and processing, IF often lacks MFGM and phospholipids, which affects infants' digestion, absorption and metabolism of fat. Commercial preparation of IF attempts to imitate the nutritional components of breast milk from the interface structure of breast milk fat droplet membrane. For example, most of the IFs currently available on the market use plant-based phospholipids (soybean phospholipids) or animal-based phospholipids (cow's milk phospholipids) to make up for the lack of phospholipids. These added mixed plant oils and phospholipids cannot completely simulate the composition of breast milk fat droplets.

[0004] Therefore, those skilled in the art are eager to develop a compound phospholipid that simulates the composition and structure of breast milk phospholipids, so as to reduce the occurrence of inflammation and allergic reactions in infants and young children, improve digestion and metabolism, and avoid the phenomenon of insufficient fat utilization. Summary of the invention

[0005] The present invention aims to solve the technical problems in the prior art that breast milk lecithin induces inflammation and allergic reactions in infants and young children and insufficient fat utilization, and provides a simulated breast milk lecithin with enriched sphingomyelin, a preparation method and application thereof.

[0006] One of the purposes of the present invention is to provide a method for preparing simulated breast milk phospholipids enriched with sphingomyelin, the preparation method comprising the following steps:

[0007] S1: Using yak butter sphingomyelin as the main raw material for enriching sphingomyelin, adding chemical catalyst chloroform:methanol, placing it in a protective gas for enrichment, and obtaining yak butter sphingomyelin enriched product;

[0008] S2: The contents of main phospholipids and long-chain fatty acids in breast milk were detected. Based on the above detection results, the yak butter sphingomyelin enriched product obtained in S1 was used as raw materials for compounding with exogenous compound phospholipids. The above different ratios were scored by Python scoring method, and the ratio with the highest score was selected for compounding in protective gas to obtain a compound product;

[0009] S3: The compound product obtained in S2 is mixed with ultrapure water to form a phospholipid solution, which is placed in a protective gas and magnetically stirred at 45° C. for 8-16 hours to obtain an emulsion aqueous phase;

[0010] S4: adding vegetable oil to the aqueous phase of the emulsion obtained in S3, placing it in a protective gas and high-speed shearing at 10000 r / min for 10 min to obtain an emulsion;

[0011] S5: The emulsion obtained in S4 is homogenized in a protective gas at 25 MPa for 2 times to obtain simulated breast milk phospholipids enriched with sphingomyelin.

[0012] In a preferred embodiment of the present invention, the enrichment step in S1 is: placing yak butter and chloroform:methanol in a 45°C magnetic stirring water bath, and shaking at a constant temperature for 60 minutes; taking the n-hexane layer, and using a rotary evaporator for rotary evaporation at a temperature of 50°C for 20-60 minutes.

[0013] In a preferred embodiment of the present invention, the main phospholipids in the breast milk phospholipids in S2 are glycerophospholipids and sphingolipids; the glycerophospholipids in the breast milk phospholipids are: phosphatidylcholine PC, phosphatidylethanolamine PE, phosphatidylinositol PI and phosphatidylserine PS; the sphingolipids in the breast milk phospholipids are sphingomyelin SM.

[0014] In a preferred embodiment of the present invention, the long-chain fatty acids in the breast milk lecithin in S2 are total fatty acids with a content greater than 1% in breast milk lecithin, which are: C16:0, C18:0, C18:1 and C18:2.

[0015] In a preferred embodiment of the present invention, the exogenous compound phospholipids in S2 include egg yolk phosphatidylcholine EPL, soybean phospholipids SPL and sunflower phospholipids SSPL.

[0016] In a preferred embodiment of the present invention, the Python scoring method in S2 is:

[0017] G=G1+G 2，

[0018] Among them, G is a total score of 100 points, G1 is a total score of 50 points for the main phospholipid conditions, and G2 is a total score of 50 points for the long-chain fatty acid conditions; G1 and G2 are:

[0019]

[0020] Where n represents the number of major phospholipids or long-chain fatty acids, and Ei(PL) represents the score of the i-th major phospholipid:

[0021]

[0022] Where Ci(PL) is the floating coefficient of the i-th major phospholipid in breast milk,

[0023]

[0024] Wherein, Bi(PL) is the average value of the content of the i-th main phospholipid in the compound product after mixing different raw material ratios, and Ai(PL) is the range value of the content of the i-th main phospholipid in breast milk;

[0025] Di(PL) is the average value of the content of the i-th major phospholipid in breast milk, is the weight of the i-th major phospholipid content in breast milk;

[0026] Ei(FAS) represents the score of the i-th long-chain fatty acid condition:

[0027]

[0028] Wherein, Ci(FAS) is the floating coefficient of the i-th long-chain fatty acid in breast milk,

[0029]

[0030] Wherein, Bi(FAS) is the average value of the i-th long-chain fatty acid in the compound product after mixing different raw material ratios, and Ai(FAS) is the range value of the i-th long-chain fatty acid content in breast milk;

[0031] Di(FAS) is the average value of the i-th long-chain fatty acid content in breast milk, is the weight of the i-th long-chain fatty acid content in breast milk;

[0032] When Bi(X)>Ai(X) maximum value, Ai(X) takes the breast milk range Max;

[0033] When Bi(X)<Ai(X) minimum value, Ai(X) takes the breast milk range Min;

[0034] When Bi(X) is within the range of Ai(X), Ci(X) = 0;

[0035] X is FAS or PL.

[0036] In a preferred embodiment of the present invention, the concentration of the phospholipid solution in S3 is 2% (W / V).

[0037] In a preferred embodiment of the present invention, the vegetable oil in S4 is any one of soybean oil, corn oil, sunflower oil, coconut oil, linseed oil, walnut oil or rapeseed oil.

[0038] The second object of the present invention is to provide a simulated breast milk phospholipid supplemented with enriched sphingomyelin, wherein the simulated breast milk phospholipid is obtained by the above-mentioned preparation method.

[0039] The third object of the present invention is to provide the use of the above-mentioned simulated breast milk phospholipids in the preparation of infant formula milk powder.

[0040] Beneficial effects of the present invention: The present invention provides a simulated breast milk phospholipid enriched with sphingomyelin and a preparation method thereof. Compared with the prior art, the simulated breast milk phospholipid obtained by the Python scoring tool is highly similar to the phospholipid composition of healthy breast milk; the ultra-high-definition resolution microscope imaging results show that the simulated breast milk phospholipid provided by the present invention is more similar to the imaging results of healthy breast milk, both of which are phospholipids and proteins compositely wrapped on the triglyceride surface to improve the formation of milk fat globule membrane and phospholipids. It can be seen that the simulated breast milk phospholipid obtained by the preparation method provided by the present invention has the advantages of high quality and high safety.

[0041] The present invention obtains a more accurate compounding ratio through the Python scoring tool, and the obtained simulated breast milk phospholipids are more similar to healthy breast milk, saving time cost; the present invention divides yak butter phospholipids into two major categories, including sphingomyelin and other phospholipids, through enrichment reaction, and uses chloroform: methanol extraction to increase the relative content of yak butter sphingomyelin in the obtained yak butter phospholipid enrichment product, further improving the quality and nutritional value of simulated breast milk phospholipids; the present invention uses the difference in melting points to remove chloroform: methanol by rotary evaporation fractionation, reducing the residual harmful substances in simulated breast milk phospholipids, and improving product quality and safety. The simulated breast milk phospholipids provided by the present invention can be used to prepare infant formula milk powder, reduce the occurrence of inflammation and allergic reactions in infants and young children, and improve fat utilization. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 This is an ultra-high-resolution microscope image. DETAILED DESCRIPTION

[0043] Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It should be particularly noted that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content and scope of the present invention to implement and apply the technology of the present invention.

[0044] In order to make the purpose, technical scheme and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific embodiments and the accompanying drawings of the specification. The test methods used in the following examples are conventional methods unless otherwise specified, and the materials, reagents, methods and instruments used are conventional materials, reagents, methods and instruments in the art unless otherwise specified, and can be obtained by those skilled in the art through commercial channels.

[0045] Embodiment 1:

[0046] In this embodiment, the main phospholipids and long-chain fatty acid contents of breast milk phospholipids are detected, wherein the main phospholipids are glycerophospholipids and sphingolipids, wherein the four main substances in the glycerophospholipids are phosphatidylcholine PC, phosphatidylethanolamine PE, phosphatidylinositol PI and phosphatidylserine PS, respectively, and the main sphingolipid in the breast milk is sphingomyelin SM; the long-chain fatty acids are total fatty acids with a content greater than 1% in breast milk phospholipids, including C16:0, C18:0, C18:1, and C18:2; the test results are shown in Table 1.

[0047] Table 1

[0048]

[0049]

[0050] In this example, yak butter sphingomyelin is used as the main raw material for enriching sphingomyelin. Yak butter and chloroform:methanol are placed in a 45°C magnetic stirring water bath and the constant temperature oscillation time is 60 minutes. The n-hexane layer is taken and rotary evaporated using a rotary evaporator at a temperature of 50°C for 20-60 minutes to obtain a yak butter sphingomyelin enriched product.

[0051] In this example, the contents of main phospholipids and long-chain fatty acids in the yak butter sphingomyelin enriched product SMPL, egg yolk lecithin EPL, soybean lecithin SPL and sunflower lecithin SSPL prepared above were detected. The results are shown in Table 2. Among them, the PE content in SPL is the highest, the PC content in EPL is the highest, SM exists only in SMPL, the PI content in SPL is the highest, and the PS content in SSPL is the highest; the C (16: 0) and C (18: 0) in SMPL are the highest, the C (18: 1) content in EPL is the highest, and the C (18: 2) content in SPL is the highest.

[0052] Table 2

[0053] SPL EPL SSPL SMPL PE 34.06±0.89 25.15±0.42 20.69±0.26 12.65±0.33 PC 35.51±1.08 64.12±4.96 60.40±2.35 16.12±2.39 SM - - - 71.24±4.10 PI 30.43±0.32 3.71±0.02 3.39±0.12 - PS - 7.01±0.39 15.50±0.45 - C(16：0) 27.76±0.61 38.73±0.37 29.49±1.40 41.18±0.20 C(18：0) 5.08±0.21 14.24±0.93 5.79±0.37 30.57±0.38 C(18：1) 19.93±1.85 40.49±0.21 19.45±0.23 26.53±0.86 C(18：2) 47.23±0.73 6.55±0.06 45.27±1.93 1.72±0.14

[0054] Embodiment 2:

[0055] S1: The yak butter sphingomyelin enriched product SMPL obtained in Example 1 and exogenous composite phospholipids (egg yolk lecithin EPL, soybean lecithin SPL and sunflower lecithin SSPL) were used as raw materials, and different raw material ratios were obtained based on the test results of Table 2 in Example 1. Some of the ratios are shown in Table 3;

[0056] S2: The ratio obtained in S1 is evaluated by the Python scoring method to obtain the raw material ratio, and the raw materials are compounded in protective gas according to the above ratios to obtain compound products respectively, and the main phospholipids and long-chain fatty acid contents of the compound products under different ratio conditions are detected; and the above different ratios are scored by the Python scoring method. The scoring results of some ratios are shown in Table 3. The ratio with the highest score is selected as the best ratio to obtain the best compound product;

[0057] The Python scoring method is:

[0058] G=G1+G 2，

[0059] Among them, G is a total score of 100 points, G1 is a total score of 50 points for the main phospholipid conditions, and G2 is a total score of 50 points for the long-chain fatty acid conditions. G1 and G2 are:

[0060]

[0061] Where n represents the number of major phospholipids or long-chain fatty acids, and Ei(PL) represents the score of the i-th major phospholipid:

[0062]

[0063] Among them, Ci(PL) is the floating coefficient of the main phospholipids in breast milk,

[0064]

[0065] Among them, Bi(PL) is the average value of the main phospholipid content in the compound product after mixing different raw material ratios, and Ai(PL) is the range value of the main phospholipid content in breast milk;

[0066] In this embodiment S1, the Python tool is used to obtain the composite products prepared in different ratios, and Bi(PL) is input based on the main phospholipid content detection results of the composite products under the above different ratio conditions; based on the detection results in Table 1, the input range of Ai(PL) in this embodiment is PE: 17.19-30.83%, PC: 16.99-35.38%, SM: 36.73-38.52%, PI: 2.95-7.33%, PS: 4.75-6.30%;

[0067] Di(PL) is the average value of the main phospholipid content in breast milk. is the weight of the main phospholipid content in breast milk;

[0068] Based on the test results in Table 1, in this embodiment, Di(PL) inputs PE: 25.67%, PC: 24.74%, SM: 38.25%, PI: 5.58%, PS: 5.74%;

[0069] Ei(FAS) represents the score of the i-th long-chain fatty acid condition:

[0070]

[0071] Wherein, Ci(FAS) is the floating coefficient of long-chain fatty acids in breast milk,

[0072]

[0073] Among them, Bi(FAS) is the average value of long-chain fatty acids in the compound product after mixing different raw material ratios, and Ai(FAS) is the range value of long-chain fatty acid content in breast milk;

[0074] In this embodiment S1, the Python tool is used to obtain the composite products prepared with different ratios, and Bi (FAS) is input based on the long-chain fatty acid content test results of the composite products under the above different ratio conditions; based on the test results in Table 1, the input range of Ai (FAS) in this embodiment is C (16: 0): 19.32-38.91%, C (18: 0): 22.15-41.34%, C (18: 1): 13.85-31.26%, C (18: 2): 12.77-23.42%;

[0075] Di(FAS) is the average value of long-chain fatty acids in breast milk. is the weight of the long-chain fatty acid content in breast milk;

[0076] In this embodiment, Di(FAS) is respectively input as C(16:0): 32.15%, C(18:0): 31.40%, C(18:1): 20.26%, C(18:2): 16.19%;

[0077] When Bi(X)>Ai(X) maximum value, Ai(X) takes the breast milk range Max;

[0078] When Bi(X)<Ai(X) minimum value, Ai(X) takes the breast milk range Min;

[0079] When Bi(X) is within the range of Ai(X), Ci(X) = 0;

[0080] X is FAS or PL.

[0081] Table 3

[0082] Score / % SPL EPL SSPL SMPL 88.315 0.39 0.11 0.18 0.32 88.232 0.41 0.09 0.15 0.35 88.178 0.40 0.11 0.24 0.25 88.150 0.37 0.13 0.29 0.21 87.959 0.41 0.09 0.18 0.32 87.953 0.45 0.05 0.19 0.31 87.327 0.47 0.03 0.24 0.26 87.219 0.02 0.49 0.10 0.39 87.033 0.03 0.49 0.16 0.32 87.011 0.04 0.49 0.11 0.36

[0083] Example 3: Water and homogenization of simulated breast milk lecithin

[0084] S1: Compounding the raw material ratio with the highest Python score in Example 2 (39% SPL, 11% EPL, 18% SSPL and 32% SMPL), mixing the obtained compounded product with ultrapure water to form a 2% (W / V) phospholipid solution, placing it at 45° C. with magnetic stirring for 8-16 hours to obtain an emulsion aqueous phase;

[0085] S2: Add vegetable oil to the aqueous phase of the emulsion obtained in S1, high-speed shear for 10 min at 10,000 r / min, and then homogenize at 25 MPa, and homogenize twice to obtain simulated breast milk phospholipids enriched with sphingomyelin.

[0086] Comparative Example 1: healthy breast milk.

[0087] Comparative Example 2: Commercially available infant formula milk powder with added soy lecithin.

[0088] Effect experiment:

[0089] (1) The simulated breast milk phospholipids prepared in Example 3 and the healthy breast milk in Comparative Example 1 were tested for the contents of main phospholipids and long-chain fatty acids. The test results are shown in Table 4. The simulated breast milk phospholipids prepared in this example are highly similar to the phospholipid composition of healthy breast milk.

[0090] Table 4

[0091] Grouping PE PC SM PI PS C(16:0) C(18:0) C(18:1) C(18:2) Example 3 27.39 26.10 35.34 5.93 5.24 34.38 23.44 24.07 18.09 Comparative Example 1 25.67 24.74 38.25 5.58 5.74 32.15 31.4 20.26 16.19

[0092] (2) The present invention uses an ultra-high resolution microscope system to image and observe the microstructure of the simulated breast milk phospholipids prepared in Example 3, the healthy breast milk in Comparative Example 1, and the commercially available infant formula milk powder with added soybean lecithin in Comparative Example 2, wherein the emulsion samples (0.2 mL) in Example 3 and Comparative Examples 1-2 are first diluted to 10 mL with ultrapure water and gently mixed. The phospholipids at the lipid droplet interface are labeled with the fluorescent probe Rd-DOPE at a concentration of 1 mg / mL (chloroform configuration); 1 mg / mL (Milli-Q configuration) of FCF is used to label the protein concentration at the interface of the simulated fat globule lipid droplets. 120 μL of each of the above samples is mixed evenly with 15 μL of Rd-DOPE and 60 μL of FCF, and incubated for 1 hour at room temperature and in the dark. 0.5 μL of the above mixture is dropped on a glass slide, and nail polish is applied to the edge of the cover glass to fix the sample in an appropriate position to prevent it from drying, and then observation is performed.

[0093] The sample observation temperature was 25 °C, the excitation wavelengths corresponding to Rd-DOPE and FCF were 568 nm and 488 nm, respectively, and the super-resolution microscope was equipped with a 63x oil lens with a numerical aperture of 1.42.

[0094] Observation results such as Figure 1 As shown, the ultra-high resolution microscopy imaging of simulated breast milk phospholipids prepared in Example 3 is more similar to the healthy breast milk in Comparative Example 1, both of which are phospholipids and proteins complexed and wrapped on the triglyceride surface; while the commercially available infant formula milk powder with added soybean lecithin in Comparative Example 2, ultra-high resolution microscopy imaging shows a large range of whey protein and casein aggregation, which reduces the formation of milk fat globule membrane and phospholipids, thereby affecting the digestion, absorption and metabolism of fat by infants and young children.

[0095] The contents not described in detail in the specification of the present invention are well-known technologies for those skilled in the art. Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention should be based on the definition of the claims.

Claims

1. A method for preparing simulated breast milk phospholipids enriched with sphingomyelin, characterized in that: The preparation method comprises the following steps: S1: Using yak butter sphingomyelin as the main raw material for enriching sphingomyelin, adding chemical catalyst chloroform:methanol, placing it in a protective gas for enrichment, and obtaining yak butter sphingomyelin enriched product; S2: The contents of main phospholipids and long-chain fatty acids in breast milk were detected. Based on the above detection results, the yak butter sphingomyelin enriched product obtained in S1 was used as raw materials for compounding with exogenous compound phospholipids. The above different ratios were scored by Python scoring method, and the ratio with the highest score was selected for compounding in protective gas to obtain a compound product; S3: The compound product obtained in S2 is mixed with ultrapure water to form a phospholipid solution, which is placed in a protective gas and magnetically stirred at 45° C. for 8-16 hours to obtain an emulsion aqueous phase; S4: adding vegetable oil to the aqueous phase of the emulsion obtained in S3, placing it in a protective gas and high-speed shearing at 10000 r / min for 10 min to obtain an emulsion; S5: The emulsion obtained in S4 is homogenized in a protective gas at 25 MPa for 2 times to obtain simulated breast milk phospholipids enriched with sphingomyelin.

2. The preparation method according to claim 1, characterized in that: The enrichment steps described in S1 are: placing yak butter and chloroform:methanol in a 45°C magnetic stirring water bath, and shaking at a constant temperature for 60 minutes; taking the n-hexane layer, and using a rotary evaporator for rotary evaporation at a temperature of 50°C for 20-60 minutes.

3. The preparation method according to claim 1, characterized in that: The main phospholipids in the breast milk phospholipids described in S2 are glycerophospholipids and sphingolipids; the glycerophospholipids in the breast milk phospholipids are: phosphatidylcholine PC, phosphatidylethanolamine PE, phosphatidylinositol PI and phosphatidylserine PS; the sphingolipids in the breast milk phospholipids are sphingomyelin SM.

4. The preparation method according to claim 1, characterized in that: The long-chain fatty acids in the breast milk lecithin described in S2 are total fatty acids with a content greater than 1% in the breast milk lecithin, which are: C16:0, C18:0, C18:1 and C18:

2.

5. The preparation method according to claim 1, characterized in that: The exogenous compound phospholipids in S2 include egg yolk lecithin EPL, soybean lecithin SPL and sunflower lecithin SSPL.

6. The preparation method according to claim 1, characterized in that: The Python scoring method described in S2 is: G=G1+G 2， Among them, G is a total score of 100 points, G1 is a total score of 50 points for the main phospholipid conditions, and G2 is a total score of 50 points for the long-chain fatty acid conditions; G1 and G2 are: Where n represents the number of major phospholipids or long-chain fatty acids, and Ei(PL) represents the score of the i-th major phospholipid: Where Ci(PL) is the floating coefficient of the i-th major phospholipid in breast milk, Wherein, Bi(PL) is the average value of the content of the i-th main phospholipid in the compound product after mixing different raw material ratios, and Ai(PL) is the range value of the content of the i-th main phospholipid in breast milk; Di(PL) is the average value of the content of the i-th major phospholipid in breast milk, is the weight of the i-th major phospholipid content in breast milk; Ei(FAS) represents the score of the i-th long-chain fatty acid condition: Wherein, Ci(FAS) is the floating coefficient of the i-th long-chain fatty acid in breast milk, Wherein, Bi(FAS) is the average value of the i-th long-chain fatty acid in the compound product after mixing different raw material ratios, and Ai(FAS) is the range value of the i-th long-chain fatty acid content in breast milk; Di(FAS) is the average value of the i-th long-chain fatty acid content in breast milk, is the weight of the i-th long-chain fatty acid content in breast milk; When Bi(X)>Ai(X) maximum value, Ai(X) takes the breast milk range Max; When Bi(X)<Ai(X) minimum value, Ai(X) takes the breast milk range Min; When Bi(X) is within the range of Ai(X), Ci(X) = 0; X is FAS or PL.

7. The preparation method according to claim 1, characterized in that: The concentration of the phospholipid solution in S3 is 2% (W / V).

8. The preparation method according to claim 1, characterized in that: The vegetable oil in S4 is any one of soybean oil, corn oil, sunflower oil, coconut oil, linseed oil, walnut oil or rapeseed oil.

9. A simulated breast milk phospholipid enriched with sphingomyelin, characterized in that: The simulated breast milk phospholipids are obtained by the preparation method according to any one of claims 1 to 8.

10. Use of the simulated breast milk phospholipids according to claim 9 in preparing infant formula milk powder.

Images